Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

828 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma; a population-based analysis.
Meeuwes FO, Brink M, van der Poel MWM, Kersten MJ, Wondergem M, Mutsaers PGNJ, Böhmer L, Woei-A-Jin S, Visser O, Oostvogels R, Jansen PM, Diepstra A, Snijders TJF, Plattel WJ, Huls GA, Vermaat JSP, Nijland M. Meeuwes FO, et al. Among authors: brink m. Eur J Cancer. 2022 Nov;176:100-109. doi: 10.1016/j.ejca.2022.09.008. Epub 2022 Oct 5. Eur J Cancer. 2022. PMID: 36208568 Free article.
Trends in incidence, primary treatment and survival in chronic myelomonocytic leukaemia: a population-based study of 1359 patients diagnosed in the Netherlands from 1989 to 2012.
Dinmohamed AG, Brink M, Visser O, Sonneveld P, van de Loosdrecht AA, Jongen-Lavrencic M, de Greef GE. Dinmohamed AG, et al. Among authors: brink m. Br J Haematol. 2015 Nov;171(3):436-9. doi: 10.1111/bjh.13414. Epub 2015 Apr 8. Br J Haematol. 2015. PMID: 25854120 Free article. No abstract available.
Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study.
Brink M, Kahle XU, Vermaat JSP, Zijlstra JM, Chamuleau M, Kersten MJ, Durmaz M, Plattel WJ, Lugtenburg PJ, Stevens W, Mous R, de Vries EGE, van der Poel MWM, Panday PVN, Huls G, van Meerten T, Nijland M. Brink M, et al. Blood Adv. 2021 Aug 10;5(15):2958-2964. doi: 10.1182/bloodadvances.2021004295. Blood Adv. 2021. PMID: 34338755 Free PMC article.
Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands.
Brink M, Minnema MC, Visser O, Levin MD, Posthuma EFMW, Broijl A, Sonneveld P, van der Klift M, Roeloffzen WWH, Westerman M, van Rooijen CR, Geerts PAF, Zweegman S, van de Donk NWCJ, Dinmohamed AG. Brink M, et al. Blood Cancer J. 2022 Mar 15;12(3):41. doi: 10.1038/s41408-022-00640-6. Blood Cancer J. 2022. PMID: 35292622 Free PMC article. No abstract available.
R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma.
Al-Sarayfi D, Meeuwes FO, Durmaz M, Issa DE, Brouwer RE, Beeker A, van Rhenen A, Mutsaers PGNJ, Böhmer LH, van der Poel MWM, Te Boome L, van Meerten T, Chamuleau MED, Zijlstra JM, Brink M, Nijland M. Al-Sarayfi D, et al. Among authors: brink m. Blood Cancer J. 2022 Sep 2;12(9):125. doi: 10.1038/s41408-022-00723-4. Blood Cancer J. 2022. PMID: 36055987 Free PMC article. No abstract available.
828 results